Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KJ015 in HER2-expressing solid tumors
NCT07036185Phase 1Not yet recruiting
- Sponsor
- Shanghai Bao Pharmaceuticals Co., Ltd.
- Start
- Jun 2025
- Primary completion
- Dec 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of KJ015 in gastric cancer (GC), gastroesophageal junction cancer, breast cancer and 4 more, sponsored by Shanghai Bao Pharmaceuticals Co., Ltd. Primary endpoints: Adverse Event collection and assessment up to 24 weeks and Backfill part recommended extension dose (RED) up to 24 weeks. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
KJ015
03
Conditions
gastric cancer (GC)gastroesophageal junction cancerbreast cancercolorectal cancer (CRC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07036185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07036185.